BruceUa abortus may be useful as a component of vaccines. This is because it possesses several unique properties as a carrier that enable it to stimulate human B cells even in the relative absence of T cells. Human immunodeficiency virus type 1 proteins conjugated to B. abortus could induce neutralizing antibodies against human immunodeficiency virus type 1. Recently we showed that the characteristics of lipopolysaccharide (LPS) derived from B. abortus are similar to those of the whole bacterium in that the LPS acts as a T-independent type 1 carrier in mice. In this study we wanted to determine whether LPS derived from B. abortus is associated with the adverse effects seen with other bacterial endotoxins. LPS purified from B. abortus by butanol extraction was shown to have <2% (wt/wt) contamination by protein and < 1% (wt/wt) contamination by nucleic acids and to contain 1% (wt/wt) ketodeoxyoctanic acid. Compared with LPS derived from Escherichia coli, B. abortus LPS was 10,000-fold less potent in eliciting fever in rabbits, 268-fold less potent in killing D-galactosamine-sensitized mice, and 1,400-fold and 400-fold less potent in inducing interleukin-1 and tumor necrosis factor alpha production, respectively. These results suggest that B. abortus LPS is much less likely than the LPS from E. coli to evoke endotoxic shock; therefore, it may be feasible to incorporate B. abortus as a component of vaccines.
Inactivated Brucella abortus was shown to behave as a T-independent type 1 carrier in the activation of human B cells. In these experiments, trinitrophenyl was conjugated to B. abortus. This conjugate stimulated human primary immunoglobulin M antibody responses after T-cell depletion (7) . Furthermore, the trinitrophenyl-B. abortus conjugate elicited immunoglobulin responses with B cells from adults, neonates, and patients with an X-linked immunodeficiency, Wiskott-Aldrich syndrome (8) . In view of these unique qualities, we have considered B. abortus as a component of immunoconjugates for the development of vaccines for humans, including immunodeficient patients. In preliminary studies, mice were immunized with human immunodeficiency virus type 1 proteins conjugated to B. abortus (9) . Neutralizing anti-human immunodeficiency virus antibodies were generated, even in mice that had been depleted of T helper cells by anti-CD4 treatment. Recently we showed that lipopolysaccharide (LPS) derived from B. abortus (LPS-BA) has characteristics similar to those of the whole bacterium in that LPS-BA acts as a T-independent type 1 carrier in mice (11) . In light of these results, it may be possible to substitute LPS-BA for B. abortus in vaccine development.
A potential problem in the use of B. abortus or LPS-BA as a carrier in vaccines designed for human use is that LPS from gram-negative bacteria can induce endotoxic shock. Septic shock is associated with release of multiple mediators from phagocytic and endothelial cells. In particular, interleukin-13 (IL-1,B) (5) and tumor necrosis factor alpha * Corresponding author.
(TNF-a) (4) are released by monocytes and macrophages in response to LPS.
In this study, we compared the effect of LPS-BA with that of LPS from Escherichia coli (LPS-EC) in various systems to assess whether LPS-BA would be likely to induce endotoxic shock in humans.
MATERIALS AND METHODS
Extraction of LPS from B. abortus. B. abortus 1119 was propagated in a fermentor (2) , and the LPS was extracted by the n-butanol-water procedure of Morrison and Leive (16) (20) . This latter procedure is considered a mild extraction in which the bacterial cells are not disrupted. Briefly, 50 g of live B. abortus organisms were extracted in 400 ml of water-saturated n-butanol (99%) at 4°C. The aqueous phase was obtained by using a separatory funnel, centrifuged to remove insoluble material, and pooled. To precipitate LPS, 4 Lethality in mice. The lethality of the LPSs in mice was assessed as described by Galanos et al. (6) . Groups of 10 C3HIHeN mice were intraperitoneally injected simultaneously with 18 mg of D-galactosamine (Sigma) per mouse and increasing doses of either LPS-BA or LPS-EC in 0.2 ml of phosphate-buffered saline. The mice were observed for 4 days for the development of neurological signs and death. 
RESULTS
Characterization of LPS-BA. The LPS-BA obtained by the butanol-water partition method contained less than 2% protein by weight, as determined by the Lowry et al. method (12) . Nucleic acid contamination, measured by spectrophotometry at 260 nm, was <1% by weight. Ketodeoxyoctonate, which is a unique component of bacterial LPS, was found to be 1% by weight. This latter value is in agreement with ketodeoxyoctonate values obtained previously for highly purified LPS-BA (20) . In the LAL assay, 1 mg of LPS-BA contained 107 endotoxin units, whereas 1 mg of LPS-EC contained 104 endotoxin units. The increased reactivity of LPS-BA compared with that of LPS-EC in the LAL assay is probably due to its different lipid A structure (13, 14) .
SDS-PAGE has been used for characterization of LPS (20, 24) . The high-molecular-weight aggregates of LPS dissociate into monomers complexed with SDS due to hydrophobic binding of SDS to the lipid A of LPS (13, 24) . The LPS-BA 0 chain is composed of a single sugar repeating unit, a linear unbranched homopolymer of 1,2-linked 4,6-D-mannosopyranosyl units terminated at its reducing end by a minor core oligosaccharide component (3, 14) . LPS-BA was added to 14% polyacrylamide SDS-PAGE gels (Fig. 1 ) stained with silver, resulting in patterns seen previously with LPS-BA (20) . Lanes 2 and 3 show patterns obtained with 5 and 10 ,ug of LPS-BA per ml, respectively. The profile consists of a fast-migrating band of low M, representing the lipid A plus the core oligosaccharide components of the LPS. The slowly migrating components appear as a smear and represent the intact LPS. The heterogeneity that causes the smear is caused by the presence of the 0 side chain with variable numbers of single repeating units (15) . Lane 1 shows the pattern obtained with LPS-EC. The LPS-EC has a fastmigrating band, similar to that of LPS-BA, that is probably lipid A. In contrast to the LPS-BA, the mature form of LPS-EC migrates as a banded pattern rather than a smear, because the sugar units of LPS-EC consist of four rather than one sugar molecule. When an excess of LPS-BA was added (lane 3), a dense band was seen at approximately 25,000 Mr. This probably represents the covalently bound protein described by others (15, 19) , which in our experience was retained even after proteinase K treatment. (Fig. 2) . The dose of LPS that induced 50% of the maximal increase in temperature (EC50) for LPS-BA, 3.6 x 10-mg/ml, was approximately 10,000-fold greater than the EC50 for LPS-EC, which was 2.7 x 10-7 mg/ml. These values were obtained from linear regression analyses ( Fig. 2, insert ; r values of .0.9) and indicate that LPS-BA is less pyrogenic than LPS-EC and would be less likely to produce endotoxic shock. The EC50 for LPS-BA represents 10 endotoxin units. Since 350 endotoxin units are allowed per dose (22) , a dose of 126 x 10-3 mg of LPS-BA per ml, which is fivefold higher than the optimal immunogenic dose in mice (11), would be permitted.
Lethality in mice. Mice were sensitized to LPS with D-galactosamine (6), injected with increasing doses of LPS, and then observed for 4 days for signs of toxicity. The lethality data are presented in Fig. 3 . They represent mean values from five separate experiments that were subjected to exponential regression analysis (rvalues of .0.85). The dose that induced 50% mortality (LD50) for LPS-EC was determined to be 336.4 ng per mouse, whereas the LD50 for LPS-BA was 90,064.2 ng per mouse. Therefore, LPS-EC was 267.7 times more potent than LPS-BA in causing death in mice.
IL-113 and TNF-a release. Since IL-1,3 and TNF-a have been implicated in the pathogenesis of endotoxic shock (4, 5) , it was important to determine what effect LPS-BA had on their release from monocytes. Human monocytes were stimulated with LPS-BA or LPS-EC, and IL-1, release was measured after 18 h. The mean values from five separate experiments are shown in Fig. 4 . Maximal release of IL-113 occurred with LPS-EC at concentrations of 1 p,g/ml, producing 13.7 ng of this monokine per ml. In contrast, the maximum concentration of IL-13 reached in response to LPS-BA was 7.1 ng/ml with a dose of 100 ,ug/ml. The Responses to LPS-EC and LPS-BA in terms of TNF-a release were also compared by linear regression analysis ( Fig. 4B ; r values of 20.87). The results are expressed as a percentage of the maximal response for each dose of either stimulus. The EC50 for LPS-EC was 0.023 ,ug/ml, whereas the EC50 for LPS-BA was 10 ,ug/ml. Based on these results, LPS-EC was 435-fold more potent than LPS-BA in inducing TNF-a secretion. The combined results obtained for and TNF-a release suggest that LPS-BA is less likely than LPS-EC to induce monocytes to release these monokines, which are involved in endotoxic shock.
DISCUSSION
Since B. abortus and LPS-BA possess unique properties, they may be useful as a component of vaccines (9) (10) (11) . In this context, it was important to assess LPS-BA as a potential inducer of endotoxic shock. This was evaluated in vivo with rabbits and mice and in vitro with human cells. When compared with LPS-EC, LPS-BA was 10,000-fold less potent in inducing fever in rabbits, 268-fold less potent in killing D-galactosamine-sensitized mice, and 1,400-and 400-fold less potent in eliciting IL-lp and TNF-a, respectively, from human monocytes. Taken together, our results suggest that LPS-BA is considerably less likely to induce endotoxic shock in humans than is LPS-EC. This latter property of LPS-BA and the fact that it has been shown to be an effective T-independent type 1 carrier for murine responses (11) 
